Stendhal Americas, S.A.   Report issue

For profit Phase 1 Phase 3
Founded: Delegación T​lalpan Mexico (1974)
Status: No NME R&D (1974)

Organization Overview

First Clinical Trial
2013
NCT02466490
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Específicos Stendhal S.A. de C.V. | Stendhal Americas, S.A.

Active Ingredients

Drugs in Phase 3 Trials (2)

fimasartan (kanarb) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

Drugs in Phase 1 Trials (2)

gemigliptin (Zemiglo) (1 trial)

metformin (glucophage) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Essential Hypertension (Phase 3)

Hypertension (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4